This page contains guidance issued by the GMMMG High Cost Drugs Subgroup. If you are an NHS healthcare professional working within the GM region and wish to submit information for consideration by the group please contact the professional secretary of the group via email

Document Title Issue Date Review Date Status
GMMMG PBR Ex Devices 2020-21 20200602 Jun 2020 20210402 Apr 2021
GMMMG PBR Ex Drugs 2020-21 20200602 Jun 2020 20210402 Apr 2021
GMMMG PBR Exclusions supporting information 20-21 20201002 Oct 2020 20211002 Oct 2021
Enabled Blueteq List 20210902 Sep 2021 updated monthly
Management of CCG-commissioned high cost drugs in the context of the COVID-19 pandemic 20200402 Apr 2020
Free of charge (FOC) medicines schemes 20200102 Jan 2020 20220102 Jan 2022
Position statement: Funding of high cost drugs when patients transition from children or adolescent services to adult services 20171002 Oct 2017 To be reviewed if national or GMMMG guidance changes
Sequential use of high cost drugs statement 20220602 Jun 2022
Commissioning framework for biologic medicines: defining best value 20180602 Jun 2018 To be reviewed if national or GMMMG guidance changes
Implementation and principles of a Greater Manchester biosimilar gainshare agreement 20170702 Jul 2017 To be reviewed if national or GMMMG guidance changes
Prescribing of high cost biosimilar biological medicines 20160702 Jul 2016 To be reviewed if national or GMMMG guidance changes
Position statement for using biologic therapies to treat adult patients with Juvenile Idiopathic Arthritis (JIA) 20171002 Oct 2017 To be reviewed if national or GMMMG guidance changes
Best Value Adalimumab: decision and uptake recommendation 20181202 Dec 2018
Botulinum toxin guidance 20200102 Jan 2020 20220102 Jan 2022
Rituximab Biosimilar Uptake Recommendation 20170602 Jun 2017 To be reviewed if national or GMMMG guidance changes
Teriparatide biosimilar uptake recommendation 20191102 Nov 2019 To be reviewed if national or GMMMG guidance changes